Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
ImmunityBio, Inc. (IBRX) had Pre-Tax Income of $-92.31M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$26.43M |
|
$-92.56M |
|
$0.14M |
|
$26.29M |
|
$97.71M |
|
$-71.28M |
|
$-21.02M |
|
|
Pre-Tax Income |
$-92.31M |
$-92.31M |
|
$-92.57M |
|
$-92.57M |
|
$-92.57M |
|
$-92.57M |
|
$-71.28M |
|
$-67.35M |
|
888.22M |
|
888.22M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$208.13M |
|
$133.00M |
|
$193.94M |
|
$402.08M |
|
$50.64M |
|
$492.08M |
|
$921.25M |
|
$971.89M |
|
$-569.82M |
|
$-584.80M |
|
$-569.82M |
|
915.62M |
|
| Cash Flow Statement Financials | |
$-165.65M |
|
$-12.01M |
|
$171.83M |
|
$143.91M |
|
$138.14M |
|
$-5.77M |
|
$19.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.11 |
|
-- |
|
-- |
|
-6.33 |
|
-0.86 |
|
99.49% |
|
-269.76% |
|
-269.76% |
|
-- |
|
-349.31% |
|
-350.26% |
|
$-167.85M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.02 |
|
1.19 |
|
75.36 |
|
16.25% |
|
15.83% |
|
-23.02% |
|
119.09% |
|
$-0.62 |
|
$-0.19 |
|
$-0.19 |
|